Pre-clinical models have demonstrated that ovarian cancer cells that express estrogen receptor (ER) could be inhibited by anti-estrogens, providing the rationale for the use of tamoxifen, letrozole, or anastrozole in this disease [7]. Here, ESR1 is linked to ovarian carcinoma.